Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

NCT00996372 | Completed Phase 3 Results DMC

• 1 other identifier: 511.130
• Study Type: interventional
• Target: 949
• Locations: 1 country
• Sites: 75

Brief Summary

The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.

Conditions

Sexual Dysfunctions, Psychological

Outcome Measures

Primary Outcomes (2)

• Change From Baseline in the Number of Satisfying Sexual Events

  A small handheld electronic device (eDiary) was used by patients to record information about sexual events. Patients were instructed to complete the eDiary every morning. When completing an eDiary entry, patients answered questions regarding their sexual events since their last eDiary entry. If patients missed or were late with their eDiary entry, they could enter information about their sexual events since their most recent entry up to a maximum of seven days in the past.

  baseline through 24 weeks

• Change From Baseline in the Score on the Female Sexual Function Index (FSFI) Desire Domain

  The FSFI© is a brief, self-administered questionnaire to assess key dimensions of sexual function in women. The scale consists of 19 items that assess sexual function over the past four weeks and yields scores in six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. The two items in the desire domain are scored from 1 to 5 (with 1 being the lowest report of desire and 5 being the highest). The raw scores of the two items are added together and then multiplied by the domain factor of 0.6. Thus, the score of the desire domain ranges from 1.2 to 6.0 (the higher the score, the higher the reported level of desire).

  baseline through 24 weeks

Secondary Outcomes (1)

• Change From Baseline on Question 13 of the Female Sexual Distress Scale Revised (FSDS R)

  change from baseline to 24 weeks

Study Arms (2)

flibanserin 100mg

EXPERIMENTAL

flibanserin 100mg po qd

Drug: flibanserin

placebo

PLACEBO COMPARATOR

placebo one tablet po qd

Drug: placebo

Interventions

flibanserin DRUG

patients will be randomized to flibanserin or placebo in a double-blind manner

flibanserin 100mg

placebo DRUG

patients will be randomized to flibanserin or placebo in a double-blind manner

placebo

Eligibility Criteria

• Age: 35 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Naturally postmenopausal women of any age with at least one ovary
• Diagnosis of Hypoactive Sexual Desire Disorder, generalized acquired type,of at least six months duration
• Stable, monogamous heterosexual relationship for at least one year
• Willing to discuss sexual issues
• Willing to engage in sexual activity at least once a month
• Normal Pap smear
• Normal mammogram
• Normal uterine lining
• Able to comply with daily use of handheld data entry device

You may not qualify if:

• Sexual dysfunctions other than HSDD, such as Sexual Aversion Disorder, Substance-induced Sexual Dysfunction, Dyspareunia, Vaginismus, Gender Identity Disorder, Paraphilia and Sexual Dysfunction due to a General Medical Condition
• Partner with inadequately treated organic or psychosexual dysfunction
• Sexual function impaired by psychiatric disorder
• Sexual function impaired by gynecological disorder
• Major Depression
• Suicidal behavior or ideation
• Major life stress that could impair sexual function
• Substance abuse

Sponsors & Collaborators

• Sprout Pharmaceuticals, Inc: lead

Study Sites (75)

511.130.01074 Boehringer Ingelheim Investigational Site

Birmingham, Alabama, United States

Location

511.130.01046 Boehringer Ingelheim Investigational Site

Huntsville, Alabama, United States

Location

511.130.01042 Boehringer Ingelheim Investigational Site

Mobile, Alabama, United States

Location

511.130.01025 Boehringer Ingelheim Investigational Site

Phoenix, Arizona, United States

Location

511.130.01073 Boehringer Ingelheim Investigational Site

Phoenix, Arizona, United States

Location

511.130.01030 Boehringer Ingelheim Investigational Site

Encinitas, California, United States

Location

511.130.01028 Boehringer Ingelheim Investigational Site

Fair Oaks, California, United States

Location

511.130.01037 Boehringer Ingelheim Investigational Site

Irvine, California, United States

Location

511.130.01022 Boehringer Ingelheim Investigational Site

Sacramento, California, United States

Location

511.130.01035 Boehringer Ingelheim Investigational Site

San Diego, California, United States

Location

511.130.01052 Boehringer Ingelheim Investigational Site

San Diego, California, United States

Location

511.130.01016 Boehringer Ingelheim Investigational Site

Torrance, California, United States

Location

511.130.01021 Boehringer Ingelheim Investigational Site

Vista, California, United States

Location

511.130.01051 Boehringer Ingelheim Investigational Site

Westlake Village, California, United States

Location

511.130.01071 Boehringer Ingelheim Investigational Site

Denver, Colorado, United States

Location

511.130.01053 Boehringer Ingelheim Investigational Site

Farmington, Connecticut, United States

Location

511.130.01015 Boehringer Ingelheim Investigational Site

Groton, Connecticut, United States

Location

511.130.01041 Boehringer Ingelheim Investigational Site

New Britain, Connecticut, United States

Location

511.130.01064 Boehringer Ingelheim Investigational Site

Newark, Delaware, United States

Location

511.130.01062 Boehringer Ingelheim Investigational Site

Washington D.C., District of Columbia, United States

Location

511.130.01003 Boehringer Ingelheim Investigational Site

Boynton Beach, Florida, United States

Location

511.130.01056 Boehringer Ingelheim Investigational Site

Clearwater, Florida, United States

Location

511.130.01065 Boehringer Ingelheim Investigational Site

Daytona Beach, Florida, United States

Location

511.130.01020 Boehringer Ingelheim Investigational Site

Miami, Florida, United States

Location

511.130.01024 Boehringer Ingelheim Investigational Site

Miami, Florida, United States

Location

511.130.01070 Boehringer Ingelheim Investigational Site

New Port Richey, Florida, United States

Location

511.130.01043 Boehringer Ingelheim Investigational Site

Orlando, Florida, United States

Location

511.130.01019 Boehringer Ingelheim Investigational Site

St. Petersburg, Florida, United States

Location

511.130.01061 Boehringer Ingelheim Investigational Site

Tampa, Florida, United States

Location

511.130.01066 Boehringer Ingelheim Investigational Site

Tampa, Florida, United States

Location

511.130.01001 Boehringer Ingelheim Investigational Site

West Palm Beach, Florida, United States

Location

511.130.01002 Boehringer Ingelheim Investigational Site

West Palm Beach, Florida, United States

Location

511.130.01009 Boehringer Ingelheim Investigational Site

Atlanta, Georgia, United States

Location

511.130.01023 Boehringer Ingelheim Investigational Site

Atlanta, Georgia, United States

Location

511.130.01008 Boehringer Ingelheim Investigational Site

Sandy Springs, Georgia, United States

Location

511.130.01044 Boehringer Ingelheim Investigational Site

Chicago, Illinois, United States

Location

511.130.01034 Boehringer Ingelheim Investigational Site

Indianapolis, Indiana, United States

Location

511.130.01067 Boehringer Ingelheim Investigational Site

Lafayette, Louisiana, United States

Location

511.130.01013 Boehringer Ingelheim Investigational Site

Baltimore, Maryland, United States

Location

511.130.01031 Boehringer Ingelheim Investigational Site

Bingham Farms, Michigan, United States

Location

511.130.01006 Boehringer Ingelheim Investigational Site

St Louis, Missouri, United States

Location

511.130.01014 Boehringer Ingelheim Investigational Site

Billings, Montana, United States

Location

511.130.01060 Boehringer Ingelheim Investigational Site

Omaha, Nebraska, United States

Location

511.130.01057 Boehringer Ingelheim Investigational Site

Las Vegas, Nevada, United States

Location

511.130.01039 Boehringer Ingelheim Investigational Site

Moorestown, New Jersey, United States

Location

511.130.01017 Boehringer Ingelheim Investigational Site

Endwell, New York, United States

Location

511.130.01047 Boehringer Ingelheim Investigational Site

New Bern, North Carolina, United States

Location

511.130.01027 Boehringer Ingelheim Investigational Site

Winston-Salem, North Carolina, United States

Location

511.130.01033 Boehringer Ingelheim Investigational Site

Cincinnati, Ohio, United States

Location

511.130.01004 Boehringer Ingelheim Investigational Site

Cleveland, Ohio, United States

Location

511.130.01050 Boehringer Ingelheim Investigational Site

Columbus, Ohio, United States

Location

511.130.01059 Boehringer Ingelheim Investigational Site

Columbus, Ohio, United States

Location

511.130.01058 Boehringer Ingelheim Investigational Site

Dayton, Ohio, United States

Location

511.130.01012 Boehringer Ingelheim Investigational Site

Mayfield Heights, Ohio, United States

Location

511.130.01072 Boehringer Ingelheim Investigational Site

Oklahoma City, Oklahoma, United States

Location

511.130.01007 Boehringer Ingelheim Investigational Site

Eugene, Oregon, United States

Location

511.130.01055 Boehringer Ingelheim Investigational Site

Pittsburgh, Pennsylvania, United States

Location

511.130.01048 Boehringer Ingelheim Investigational Site

Columbia, South Carolina, United States

Location

511.130.01068 Boehringer Ingelheim Investigational Site

Mt. Pleasant, South Carolina, United States

Location

511.130.01063 Boehringer Ingelheim Investigational Site

Knoxville, Tennessee, United States

Location

511.130.01010 Boehringer Ingelheim Investigational Site

Nashville, Tennessee, United States

Location

511.130.01036 Boehringer Ingelheim Investigational Site

Nashville, Tennessee, United States

Location

511.130.01018 Boehringer Ingelheim Investigational Site

Corpus Christi, Texas, United States

Location

511.130.01032 Boehringer Ingelheim Investigational Site

Houston, Texas, United States

Location

511.130.01011 Boehringer Ingelheim Investigational Site

Katy, Texas, United States

Location

511.130.01026 Boehringer Ingelheim Investigational Site

San Antonio, Texas, United States

Location

511.130.01005 Boehringer Ingelheim Investigational Site

Salt Lake City, Utah, United States

Location

511.130.01069 Boehringer Ingelheim Investigational Site

Sandy City, Utah, United States

Location

511.130.01040 Boehringer Ingelheim Investigational Site

Norfolk, Virginia, United States

Location

511.130.01049 Boehringer Ingelheim Investigational Site

Norfolk, Virginia, United States

Location

511.130.01029 Boehringer Ingelheim Investigational Site

Richmond, Virginia, United States

Location

511.130.01075 Boehringer Ingelheim Investigational Site

Richmond, Virginia, United States

Location

511.130.01054 Boehringer Ingelheim Investigational Site

Renton, Washington, United States

Location

511.130.01045 Boehringer Ingelheim Investigational Site

Spokane, Washington, United States

Location

511.130.01038 Boehringer Ingelheim Investigational Site

Tacoma, Washington, United States

Location

Related Publications (1)

• Simon JA, Kingsberg SA, Shumel B, Hanes V, Garcia M Jr, Sand M. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Menopause. 2014 Jun;21(6):633-40. doi: 10.1097/GME.0000000000000134.

  PMID: 24281236 DERIVED

MeSH Terms

Conditions

Sexual Dysfunctions, Psychological

Interventions

flibanserin

Condition Hierarchy (Ancestors)

Mental Disorders

Results Point of Contact

• Title: VP, Clinical Development
• Organization: Sprout Pharmaceuticals

clinicaltrials@sproutpharma.com

9198820850

Study Officials

• Boehringer Ingelheim

  Boehringer Ingelheim

  STUDY CHAIR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: GT60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 15, 2009
• First Posted: October 16, 2009
• Study Start: October 1, 2009
• Primary Completion: March 1, 2011
• Study Completion: March 1, 2011
• Last Updated: June 12, 2014
• Results First Posted: June 12, 2014

Record last verified: 2014-05

Locations

US (75)